- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Transcatheter bariatric embolotherapy useful weight loss strategy in obesity: Study
According to a recent study, obese patients lost a substantial amount of weight after transcatheter bariatric embolotherapy (TBE) of the left gastric artery (LGA).The findings of the study have been published in Journal of the American College of Cardiology.
Transcatheter bariatric embolotherapy (TBE) is a promising, nonsurgical treatment modality for weight loss that might address the treatment gap of BMI ranging between 30 and 40 kg/m2 . This percutaneous procedure involves catheter-directed embolization of the left gastric artery (LGA). The LGA provides blood supply to the gastric fundus, which contains the majority of cells that produce ghrelin, the only known orexigenic (appetite stimulating) hormone secreted from the gastrointestinal tract . Several feasibility studies have demonstrated promising effects of LGA embolization targeted specifically for weight loss using commercially available equipment.
To have agreater understanding of the matter, researchers undertook a conducted a sham-control randomized clinical trial to assess the safety and efficacy of TBE in obese individuals using an occlusive balloon microcatheter and infusion system designed for this application .
This study was a first-in-human, single-center, sham-controlled, randomized clinical trial conducted at O.B. Klinka, Prague, a European Center for Excellence for the Multidisciplinary Treatment of Obesity. This center conducted all aspects of the trial (including patient enrollment, weight management counseling, follow-up testing) except randomization and the TBE procedures, which were performed at Homolka Hospital, Prague.
For the study design, consenting patients underwent baseline testing, including a baseline endoscopy, and within 14 days, underwent randomization in a 1:1 fashion using a web-based system, and subsequently the procedure—either TBE or sham.
For the study population,Obese subjects (body mass index 35 to 55 kg/m2 ) were randomized 1:1 to either sham or TBE targeting the left gastric artery using an occlusion balloon microcatheter to administer 300- to 500-mm embolic beads. All patients entered a lifestyle counseling program. Patients and physicians performing follow-up were blind to the allocated therapy. Endoscopy was performed at baseline and 1-week post-procedure.
The primary endpoint was 6-month total body weight loss (TBWL).
On analysis, the following facts emerged.
- Eligible subjects (n ¼ 44; age 45.5 9.4 years; 8 men/36 women; body mass index 39.6 3.8 kg/m2 ) were randomized to undergo the sham or TBE procedure with no device-related complications and 1 vascular complication.
- Patients reported mild nausea and vomiting, and endoscopy revealed only minor self-limiting ulcers in 5 patients.
- At 6 months, in both the intention-to-treat and per-protocol populations, the TBWL was greater with TBE (7.4 kg/6.4% and 9.4 kg/8.3% loss, respectively) than sham (3.0 kg/2.8% and 1.9 kg/1.8%, respectively; p ¼ 0.034/0.052 and p ¼ 0.0002/0.0011, respectively).
- The TBWL was maintained with TBE at 12 months (intention-to-treat 7.8 kg/6.5% loss, per-protocol 9.3 kg/9.3% loss; p ¼ 0.0011/0.0008, p ¼ 0.0005/0.0005, respectively).
"In this prospective, randomized, sham-controlled clinical trial of transcatheter bariatric embolotherapy, obese subjects experienced well-tolerated and effective weight loss at 6-month follow-up compared with the sham control, and this weight loss was sustained at 12 months. Although a panacea for obesity is unlikely, these data indicate that, if confirmed to be safe and effective in larger future trials, embolotherapy might play an important role in mitigating this global health epidemic." said the team.
For the full article,follow the link: : Reddy VY, et al "Transcatheter bariatric embolotherapy for weight reduction in obesity" J Am Coll Cardiol 2020; DOI: 10.1016/j.jacc.2020.09.550.
Primary source: Journal of the American College of Cardiology
Dr Satabdi Saha (BDS, MDS) is a practicing pediatric dentist with a keen interest in new medical researches and updates. She has completed her BDS from North Bengal Dental College ,Darjeeling. Then she went on to secure an ALL INDIA NEET PG rank and completed her MDS from the first dental college in the country – Dr R. Ahmed Dental College and Hospital. She is currently attached to The Marwari Relief Society Hospital as a consultant along with private practice of 2 years. She has published scientific papers in national and international journals. Her strong passion of sharing knowledge with the medical fraternity has motivated her to be a part of Medical Dialogues.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751